APELLIS PHARMACEUTICALS, INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 706
- Market Cap
- $4.8B
- Website
- http://www.apellis.com
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: APL-2
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04085601
- Locations
- 🇹🇭
Thammasat University Hospital, Pathum Thani, Thailand
🇵🇭The Medical City, Pasig City, Philippines
🇵🇱Independent Public Clinical Hospital, Lubin, Poland
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03777332
- Locations
- 🇺🇸
Retina Consultants of Houston, The Woodlands, Texas, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸California Retina Consultants, Bakersfield, California, United States
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03593200
- Locations
- 🇧🇬
Acibadem City Clinic MHAT Tokuda EAD Sofia, Sofia, Bulgaria
🇷🇸Klinički centar Srbije, Belgrade, Serbia
🇧🇬Specialized Hospital for Active Treatment of Hematologic Diseases EAD, Sofia, Sofia, Bulgaria
Pegcetacoplan Long Term Safety and Efficacy Extension Study
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03531255
- Locations
- 🇧🇬
Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria
🇺🇸Baptist Cancer Center, Memphis, Tennessee, United States
🇯🇵Japanese Red Cross Nagoya Daini Hospital, Showa-ku, Aichi, Japan
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic Atrophy
- Interventions
- Drug: APL-2Other: Sham Procedure
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 637
- Registration Number
- NCT03525613
- Locations
- 🇺🇸
Southeast Retina Center, PC, Augusta, Georgia, United States
🇺🇸Mid Atlantic Retina Specialists, Hagerstown, Maryland, United States
🇺🇸National Ophthalmic Research Institute (Retina Consultants of Southwest Florida), Fort Myers, Florida, United States
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic Atrophy
- Interventions
- Drug: APL-2Other: Sham Procedure
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 621
- Registration Number
- NCT03525600
- Locations
- 🇺🇸
Long Island Vitreoretinal Consultants, Great Neck, New York, United States
🇺🇸Associated Retinal Consultants PC, Traverse City, Michigan, United States
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03500549
- Locations
- 🇫🇷
Centre Hospitalier de Saint-Quentin, Saint-Quentin, France
🇺🇸Cancer Specialists of North Florida, Jacksonville, Florida, United States
🇺🇸Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
Pegcetacoplan (APL-2) in Neovascular AMD
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03465709
- Locations
- 🇺🇸
Apellis Clinical Site, Houston, Texas, United States
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
- Conditions
- IgA NephropathyMembranous NephropathyDense Deposit DiseaseLupus NephritisC3 Glomerulonephritis
- Interventions
- Drug: APL-2
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03453619
- Locations
- 🇺🇸
Horizon Research Group, Coral Gables, Florida, United States
🇺🇸Northwest Louisiana Nephrology LLC, Shreveport, Louisiana, United States
🇺🇸Washington Nephrology Associates, Alexandria, Virginia, United States
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
- Conditions
- Cold Agglutinin DiseaseWarm Autoimmune Hemolytic Anemia
- Interventions
- Drug: APL-2
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03226678
- Locations
- 🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Tennessee Medical Center, Knoxville, Tennessee, United States